You would like to read
- Crosscope and BALCO Medical Centre partner for more effective cancer diagnosis via Al-enabled Digital Pathology Platform
- US FDA grants breakthrough designation for early-stage breast cancer detection blood test developed in India by Datar Cancer Genetics
- Saveetha Oral Cancer Institute conducts a free cancer screening and awareness program in commemoration of World Cancer Day
- Booklet on Cancer and its treatment released on World Cancer Day at Dr Kamakshi Memorial Hospital
- You HAVE TO Win This Battle - Cricketer and Cancer Survivor Yuvraj Singh's heartfelt message to Cancer patients on World Cancer Day
Mountain View (California) [US]/ Pune (Maharashtra) [India], February 28 (ANI/PR Newswire): Crosscope Inc. a leading provider of AI-enabled digital pathology software and Mindpeak Gmbh, known for building sophisticated AI tools for clinical diagnosis, today announced their partnership to integrate MIndpeak's image analysis tools into the Crosscope's Digital Pathology platform.
This partnership will enable Crosscope to expand its portfolio of AI applications and deliver end-to-end digital pathology solutions.
Mindpeak has developed tools that analyze immunohistochemically stained tissue samples by immediately detecting, classifying, and quantifying breast cancer cells. Crosscope Dx, a workflow integrated vendor-agnostic digital pathology platform will use Mindpeak's CE-marked BreastIHC and follow-on products each as a supplementary module within the workflow software which will enable pathologists with diagnostics support in the evaluation of histology images or image sections. With this strategic partnership, Crosscope will be the authorized partner of Mindpeak for India and Emerging Markets.
"This collaboration will be instrumental in leveraging the strengths of both the companies to provide end-to-end solutions for all kinds of Histopathology workflows, thereby providing best-in-class AI tools seamlessly integrated into a single platform," said Crosscope CEO - Dr Jayendra Shinde. This partnership enables the integration of image analysis solutions for ER, PR, and Ki-67 IHC stainings into Crosscope that will immensely support pathologists to improve the efficiency of their pathology labs and provide a timely diagnosis for their patients ultimately impacting their treatment and outcomes.
"With our AI software BreastIHC now also available via the Crosscope platform in the USA, Europe, and e.g. India we are making a significant contribution to the AI-adoption of pathology", explains Felix Faber, CEO of Mindpeak. Crosscope, as a leading AI software provider in digital pathology, wants to ensure that Mindpeak's cutting-edge technology is available for the pathology community to enable digital transformation in the pathology laboratories in India and emerging markets, USA and Europe.
Mindpeak, founded by Felix Faber and Dr Tobias Lang, has been developing image analysis software for pathologists based on artificial intelligence since 2018. Partnering with several international laboratories and leading pathology service providers, Mindpeak is continuously expanding its product range and developing it into an indispensable component of digitized pathology workflows with focus on aiding pathologists in primary diagnostics.
For more information visit: (https://www.mindpeak.ai) or connect on (https://twitter.com/felixfaber_ai) Twitter and (https://bit.ly/3M7bpu2) LinkedIn.
Crosscope; abbreviated for "Computational Microscope" is a medical AI software company on a mission to radically transform patient care by unlocking the power of AI. The company's Crosscope Dx software is a digital pathology platform to facilitate deploying scalable Artificial Intelligence and Computational Pathology tools to empower pathology laboratories with precision diagnostics. Crosscope's team of engineers, data scientists, and pathologists are developing a unique platform and AI approach to deliver efficient pathology workflows for increased diagnostic accuracy and productivity.
For more information visit: (https://crosscope.com) or connect on (https://twitter.com/crosscope) Twitter and (https://bit.ly/3BVvGhH)) LinkedIn.
Photo: (https://mma.prnewswire.com/media/1755210/CrosscopexMindpeak.jpg)
Logo:(https://mma.prnewswire.com/media/1755167/Crosscope_Logo.jpg)
This story is provided by PRNewswire. ANI will not be responsible in any way for the content of this article. (ANI/PR Newswire)
DISCLAIMER
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
